Eli Lilly's Foundayo Obesity Pill Shows Significant Reduction in Sleep Apnea Severity
Eli Lilly has announced positive late-stage trial results for its daily obesity pill, Foundayo, demonstrating a significant reduction in the severity of moderate-to-severe obstructive sleep apnea (OSA). In clinical studies, patients taking Foundayo experienced a substantial decrease in their apnea-hypopnea index (AHI) compared to placebo groups, with some participants achieving remission or improvement to mild OSA. The company intends to submit an application for U.S. FDA approval by the end of 2025. This development positions Foundayo as a key addition to Lilly's metabolic portfolio, following the success of its weight-loss injection Zepbound, which was previously approved for OSA treatment. The pill offers a potential alternative or supplement to traditional positive airway pressure (PAP) machines for the millions of adults suffering from sleep-related breathing disorders.
Tickers: $LLY
Topics: clinical trial results FDA approval process GLP-1 obesity treatment sleep apnea
Part of the story Eli Lilly's Foundayo Obesity Pill Shows Significant Reduction in Sleep Apnea Severity (2 articles)